Cliff Asness's DGX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 50,267 shares of Quest Diagnostics Incorporated (DGX) worth $9.85 M, representing 0.00% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2015, adding 1.19 M shares. Largest reduction occurred in Q3 2017, reducing 475,160 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -16,950 | Reduce 25.22% | 50,267 | $195.98 |
| Q4 2025 | +17,149 | Add 34.25% | 67,217 | $173.53 |
| Q3 2025 | +651 | Add 1.32% | 50,068 | $190.00 |
| Q2 2025 | -5,235 | Reduce 9.58% | 49,417 | $178.12 |
| Q1 2025 | -91,935 | Reduce 62.72% | 54,652 | $169.20 |
| Q4 2024 | -116,750 | Reduce 44.33% | 146,587 | $150.86 |
| Q3 2024 | +115,868 | Add 78.57% | 263,337 | $154.21 |
| Q2 2024 | +23,150 | Add 18.62% | 147,469 | $136.88 |
| Q1 2024 | +21,483 | Add 20.89% | 124,319 | $133.04 |
| Q4 2023 | -46,725 | Reduce 31.24% | 102,836 | $137.30 |
| Q3 2023 | -67,446 | Reduce 31.08% | 149,561 | $121.86 |
| Q2 2023 | -141,686 | Reduce 39.50% | 217,007 | $140.56 |
| Q1 2023 | -179,293 | Reduce 33.33% | 358,693 | $140.25 |
| Q4 2022 | -154,127 | Reduce 22.27% | 537,986 | $155.86 |
| Q3 2022 | -115,027 | Reduce 14.25% | 692,113 | $122.69 |
| Q2 2022 | +29,422 | Add 3.78% | 807,140 | $132.98 |
| Q1 2022 | -1,282 | Reduce 0.16% | 777,718 | $136.86 |
| Q4 2021 | -43,434 | Reduce 5.28% | 779,000 | $172.35 |
| Q3 2021 | +451,088 | Add 121.47% | 822,434 | $145.31 |
| Q2 2021 | -141,355 | Reduce 27.57% | 371,346 | $131.97 |
| Q1 2021 | -70,714 | Reduce 12.12% | 512,701 | $127.63 |
| Q4 2020 | +267,722 | Add 84.80% | 583,415 | $117.66 |
| Q3 2020 | -8,993 | Reduce 2.77% | 315,693 | $114.49 |
| Q2 2020 | -172,888 | Reduce 34.75% | 324,686 | $110.54 |
| Q1 2020 | +199,470 | Add 66.91% | 497,574 | $80.30 |
| Q4 2019 | +107,921 | Add 56.75% | 298,104 | $106.38 |
| Q3 2019 | -98,054 | Reduce 34.02% | 190,183 | $107.03 |
| Q2 2019 | -49,304 | Reduce 14.61% | 288,237 | $101.38 |
| Q1 2019 | +18,601 | Add 5.83% | 337,541 | $89.92 |
| Q4 2018 | +192,743 | Add 152.73% | 318,940 | $83.27 |
| Q3 2018 | -2,849 | Reduce 2.21% | 126,197 | $107.91 |
| Q2 2018 | -97,696 | Reduce 43.09% | 129,046 | $109.94 |
| Q1 2018 | +9,430 | Add 4.34% | 226,742 | $100.30 |
| Q4 2017 | -64,467 | Reduce 22.88% | 217,312 | $98.49 |
| Q3 2017 | -475,160 | Reduce 62.77% | 281,779 | $93.64 |
| Q2 2017 | -360,599 | Reduce 32.27% | 756,939 | $111.16 |
| Q1 2017 | -150,421 | Reduce 11.86% | 1.12 M | $98.19 |
| Q4 2016 | -6,661 | Reduce 0.52% | 1.27 M | $91.90 |
| Q3 2016 | -276,926 | Reduce 17.85% | 1.27 M | $84.63 |
| Q2 2016 | -84,874 | Reduce 5.19% | 1.55 M | $81.41 |
| Q1 2016 | +72,892 | Add 4.66% | 1.64 M | $71.45 |
| Q4 2015 | +1.19 M | Add 316.33% | 1.56 M | $71.14 |
| Q3 2015 | +245,623 | Add 189.05% | 375,548 | $61.47 |
| Q2 2015 | +102,578 | Add 375.10% | 129,925 | $72.52 |
| Q1 2015 | +27,347 | New Buy | 27,347 | $76.86 |
| Q3 2014 | -13,589 | Sold Out | 0 | $0.00 |
| Q2 2014 | +1,000 | Add 7.94% | 13,589 | $58.72 |
| Q1 2014 | -76,100 | Reduce 85.81% | 12,589 | $57.91 |
| Q4 2013 | +47,065 | Add 113.07% | 88,689 | $53.54 |
| Q3 2013 | -33,865 | Reduce 44.86% | 41,624 | $61.79 |
| Q2 2013 | +75,489 | Add 0.00% | 75,489 | $60.63 |
| Q4 2012 | +351,330 | Add 0.00% | 351,330 | $58.27 |
Cliff Asness's Quest Diagnostics Incorporated Investment FAQs
Cliff Asness first purchased Quest Diagnostics Incorporated (DGX) in Q4 2012, acquiring 351,330 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Quest Diagnostics Incorporated (DGX) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Quest Diagnostics Incorporated (DGX) was in Q4 2015, adding 1,563,528 shares worth $111.23 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 50,267 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $9.85 M.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Quest Diagnostics Incorporated (DGX) was 1,636,420 shares, as reported at the end of Q1 2016.